| Literature DB >> 35449018 |
P A J Vissers1,2, R H A Verhoeven3,4, G A P Nieuwenhuijzen5, M J Westerman6, J C H B M Luijten7, L Brom1, M de Bièvre8, J Buijsen9, T Rozema10, N Haj Mohammad11, P van Duijvendijk12, E A Kouwenhoven13, W J Eshuis14, C Rosman2, P D Siersema15, H W M van Laarhoven16.
Abstract
BACKGROUND: Among esophagogastric cancer patients, the probability of having undergone treatment with curative intent has been shown to vary, depending on the hospital of diagnosis. However, little is known about the factors that contribute to this variation. In this study, we sought to understand the organization of clinical pathways and their association with variation in practice.Entities:
Keywords: Cancer medicine; Esophageal cancer; Gastric cancer; Variation in clinical pathways
Mesh:
Year: 2022 PMID: 35449018 PMCID: PMC9022421 DOI: 10.1186/s12913-022-07845-2
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.908
The VARIATE project: a mixed methods multiple case study combining qualitative and quantitative research
All patients diagnosed with esophageal and gastric cancer in the Netherlands are registered in the Netherlands Cancer Registry (NCR). Previous multivariable multilevel analyses of potentially curable patients diagnosed in the period 2015–2017 have shown that the probability of receiving treatment with curative intent differed according to the hospital of diagnosis.1 Hospitals were divided into three tertiles: low, middle or high probability of undergoing treatment with curative intent using the hospital’s odds ratios based on random intercepts. Patients diagnosed in a hospital with a high probability of receiving treatment with curative intent had a significant better long-term survival.1 In order to obtain in-depth information and knowledge of the underlying mechanisms of hospital practice variation in proposing treatment with curative intent the VARIATE project (VariAtion in the cuRatIve treatment of esophAgeal and gasTric cancEr) was developed, which was financed by the Dutch Cancer Society Received treatment with curative intent was defined as endoscopic or surgical resection, initiation of surgery (without resection), definitive chemoradiation (external beam radiotherapy and concurrent chemotherapy; including initiation of definitive chemoradiation). Palliative treatment was defined as: palliative systemic therapy, palliative radiotherapy and best supportive care |
| The VARIATE project is a mixed methods multiple case study, which combines qualitative and quantitative research. A purposive sample2 of eight cases (i.e., hospitals) participated. These hospitals were a representative sample of Dutch hospitals regarding the probability of offering treatment with curative intent, hospital type, size, and geographical location |
| Additional quantitative data for potentially curable patients (cT1-4a or Tx, any cN, cM0) diagnosed in 2015 – 2017 was gathered in 67 hospitals in the Netherlands |
Quantitative data was analyzed according to the probability of receiving treatment with curative intent using SAS® version 9.4 (SAS Institute, Cary, North Carolina, USA). A |
The project used an iterative approach for qualitative data collection and analyses. Data collection consisted of: 1. Observations of (Upper-GI specific) MDTMs (2 – 4 MDTMs per hospital) and outpatient clinic visits (minimum of 2 outpatient clinic visits per hospital) 2. Semi-structured interviews ( 3. Focus groups with clinicians in order to validate and further enrich the results of their own hospital ( 4. Focus groups with patients diagnosed with potentially curable esophageal or gastric cancer were organized to explore factors related to their treatment choices ( |
Based on the analysis of the first 3 hospitals the following decisions regarding the quantitative and qualitative data collection in the further hospitals were made: 1. Depending on the emerging topics from previous interviews the topic list was altered 2. Clinicians in the other five hospitals were selected for interviewing through emergent sampling |
| Qualitative analyses: Interviews were audio recorded, transcribed per verbatim and summarized (all by JL), and shared with the interviewed clinicians serving as member check. Next, the interviews were reviewed and coded, open coding as described by Strauss and Corbin’s grounded theory approach was used.3 The first 11 transcripts were independently coded by two researchers (JL, PV) and discussed until consensus was reached.4 The remaining 19 transcripts were coded by JL. Using thematic content analyses emerging themes were found.5 Thereafter, through a constant comparison across and within cases (axial coding), relations were searched for and themes were identied.6 The core study group (JL, PV, RV, GN) met weekly to discuss analyses, refine the codebook and identify emerging themes. The coding process was facilitated by Atlas ti 8 software |
1. Luijten JCHBM, Vissers PAJ, Lingsma H, van Leeuwen N, Rozema T, Siersema PD, et al. Changes in hospital variation in the probability of receiving treatment with curative intent for esophageal and gastric cancer. Cancer Epidemiol. 2021;71(Pt A):101,897 2. Patton MQ. Qualitative evaluation and research methods. Thousasnd Oaks, CA: Sage. (1990) 3. Strauss AL, & Corbin, J. M.. Basics of qualitative research: Grounded theory procedures and techniques.. Thousand Oaks: Sage Publications. 1990 4. Korstjens I, Moser A. Series: Practical guidance to qualitative research. Part 4: Trustworthiness and publishing. Eur J Gen Pract. 2018;24(1):120–4 5. Green, J., Thorogood, N., Qualitative Methods for Health Research (3th edn.). London: Sage Publications.2013 6. Yin RK. Case study research: Design and methods. Thousand Oaks, CA: Sage. 1994 |
Patient and tumor characteristics of patients with esophageal or gastric cancer according to hospital with low, middle and high probability of receiving treatment with curative intent
| Esophageal cancer | Gastric cancer | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| probability | probability | |||||||||||||
| low | middle | high | low | middle | high | |||||||||
| N | % | N | % | N | % | |||||||||
| ALL | 477 | 100% | 548 | 100% | 625 | 100% | 507 | 100% | 327 | 100% | 545 | 100% | ||
| Sex | 0.75 | 0.53 | ||||||||||||
| Female | 136 | 29% | 147 | 27% | 179 | 29% | 199 | 39% | 122 | 37% | 224 | 41% | ||
| Male | 341 | 71% | 401 | 73% | 446 | 71% | 308 | 61% | 205 | 63% | 321 | 59% | ||
| Age | 0.09 | 0.72 | ||||||||||||
| < 60 | 100 | 21% | 83 | 15% | 111 | 18% | 76 | 15% | 46 | 14% | 71 | 13% | ||
| 60—74 | 239 | 50% | 287 | 52% | 340 | 54% | 169 | 33% | 122 | 37% | 195 | 36% | ||
| ≥ 75 | 138 | 29% | 178 | 32% | 174 | 28% | 262 | 52% | 159 | 49% | 279 | 51% | ||
| cT Classification | 0.59 | 0.03 | ||||||||||||
| cT1 | 28 | 6% | 35 | 6% | 34 | 5% | 21 | 4% | 12 | 4% | 29 | 5% | ||
| cT2 | 133 | 28% | 143 | 26% | 197 | 32% | 202 | 40% | 117 | 36% | 190 | 35% | ||
| cT3 | 239 | 50% | 273 | 50% | 305 | 49% | 130 | 26% | 66 | 20% | 117 | 21% | ||
| cT4 | 6 | 1% | 10 | 2% | 10 | 2% | 16 | 3% | 20 | 6% | 19 | 3% | ||
| cTX | 71 | 15% | 87 | 16% | 79 | 13% | 138 | 27% | 112 | 34% | 190 | 35% | ||
| cN Classification | 0.22 | 0.7 | ||||||||||||
| cN0 | 176 | 37% | 211 | 39% | 272 | 44% | 275 | 54% | 182 | 56% | 317 | 58% | ||
| cN + | 260 | 55% | 288 | 53% | 303 | 48% | 161 | 32% | 99 | 30% | 151 | 28% | ||
| cNX | 41 | 9% | 49 | 9% | 50 | 8% | 71 | 14% | 46 | 14% | 77 | 14% | ||
| Histology | 0.07 | 0.475 | ||||||||||||
| Adenocarcinoma | 348 | 73% | 386 | 70% | 477 | 76% | 491 | 97% | 321 | 98% | 532 | 98% | ||
| Squamous cell carcinoma | 123 | 26% | 145 | 26% | 134 | 21% | NA | NA | NA | |||||
| Not otherwise specified | 6 | 1% | 17 | 3% | 14 | 2% | 16 | 3% | 6 | 2% | 13 | 2% | ||
| Number of Comorbidities | 0.83 | 0.01 | ||||||||||||
| 0 comorbidities | 192 | 40% | 213 | 39% | 259 | 41% | 166 | 33% | 127 | 39% | 219 | 40% | ||
| 1 comorbidity | 151 | 32% | 184 | 34% | 204 | 33% | 187 | 37% | 111 | 34% | 153 | 28% | ||
| 2 or more | 116 | 24% | 117 | 21% | 141 | 23% | 135 | 27% | 74 | 23% | 150 | 28% | ||
| unknown | 18 | 4% | 34 | 6% | 21 | 3% | 19 | 4% | 15 | 5% | 23 | 4% | ||
| ECOG performance status | 0.53 | 0.001 | ||||||||||||
| ECOG 0 and 1 | 319 | 67% | 368 | 67% | 415 | 66% | 260 | 51% | 141 | 43% | 267 | 49% | ||
| ECOG 2 | 39 | 8% | 53 | 10% | 43 | 7% | 37 | 7% | 24 | 7% | 51 | 9% | ||
| ECOG 3 and 4 | 16 | 3% | 16 | 3% | 17 | 3% | 31 | 6% | 10 | 3% | 12 | 2% | ||
| Unknown ECOG | 103 | 22% | 111 | 20% | 150 | 24% | 179 | 35% | 152 | 46% | 215 | 39% | ||
Quantitative outcome parameters oesophageal and gastric cancer according to the probability of receiving treatment with curative intent
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
| | ||||||||||||||||
*Fishers exact test
bMultidisciplinary for esophageal cancer is defined as: radiation oncologist, medical oncologist and surgeon. For gastric cancer multidisciplinary is defined as medical oncologist and surgeon
Variation in the organization of clinical pathways on regional, local, and patient level
| Theme | Subtheme | Category | Summary |
|---|---|---|---|
| Regional level | Arrangements for referral of patients | • Arrangements versus no arrangements | Most hospitals were part of a regional network or collaboration in which agreements regarding referral were established. Other hospitals had no agreements at all |
• All patients • Selection of patients • Second opinion | Differences across hospitals were observed regarding patient discussion during the MDTM. Some hospitals discussed all patients, while others who discussed only a selection of patients | ||
| Centralization of care | • • Increased experience due to higher exposure to Upper-GI cases in resection centers • Decreased exposure in referral hospitals | More knowledge in resection centers and potential knowledge depletion in referral centers due to differences in exposure | |
| Organization of diagnostics and treatment | • Diagnostics conducted in the referral center and/or resection center | Arrangements regarding conducting diagnostics in the referral or resection center differed and, in most hospitals, this was described in their clinical pathways | |
• Sufficient versus insufficient • Protocols versus no protocols | The quality of the radiological images differed per referring hospital. At times if quality was insufficient, repeated radiological imaging was necessary. Some hospitals established protocols to improve the quality of radiological images | ||
• Arrangements about the hospital of treatment • Referral versus resection center ▪ Neoadjuvant treatment ▪ Adjuvant treatment ▪ Follow-up | Hospitals’ agreements differed considerably regarding the location (resection- and/or referring hospital) of neoadjuvant therapy and follow-up or the location of treatment of complications | ||
| Communication | • Consultation between centers • Difficult cases | Some resection hospitals organized overarching MDTMs with other resection centers in order to discuss difficult cases | |
• Case manager is key figure | The case manager in the resection center was an invaluable asset in the care pathway by facilitating communication between and within centers | ||
| Local level | Patient information and diagnostics | • | All hospitals used standard templates for patient discussion during an MDTM; however sometimes information was lacking, resulting in postponement of patient presetationto the next MDTM |
| • | Standard revision of radiological images of referred patients by an in-house upper-GI radiologist prior to the MDTM could lead to additional findings, such as the identification of additional metastatic locations or resectability, influencing the treatment plan in either direction | ||
| • Patient representation by clinician during the MDTM | In some hospitals, the patient is represented by a clinician (e.g., clinician from referral or resection center), while in others, the patient discussion is based on the standard templates | ||
| Organization of MDTM | • MDTM Preparation • Patient summary • Patient’s seen during outpatient clinic visit prior to MDTM • | Some hospitals conducted triage prior to the MDTM, reviewing and verifying whether all necessary diagnostic modalities were performed and all information was obtained and available, enhancing discussion, resulting in a more efficient workflow during the MDTM. If certain modalities had not been implemented, these examinations were ordered after triage so that patient information would be complete during the MDTM | |
| Setting and buildup of the MDTM | • Dealing with missing clinical information • Time-related aspects of the MDTM | Complete information available during the MDTM makes treatment decision-making (TDM) feasible. Last-minute application for discussion of patients in the MDTM leads to incomplete information. If attendees are late to attend the MDTM, knowledge remains lacking until all involved medical specialists are present to participate in the MDTM. The maximum time an MDTM should last was mentioned to be 1.5 h, since at the end fatigue set in. Because fatigue sets in toward the end of the MDTM, some hospitals discussed the new cases at the beginning of the MDTM, followed by recurring cases | |
| • | In the majority of the hospitals only oncologic upper-GI patients were discussed during the MDTM, whereas, in some hospitals, other gastroenterological cancers were also discussed | ||
| Clinicians may attend the MDTM live or by teleconference. In some non-academic resection hospitals an academic resection hospital was present during the MDTM and in some hospitals the referring clinicians were not present during the MDTM | |||
| Patient level | Standardization of clinical examinations | • Histological confirmation of potential metastases • All centers aim for histological confirmation—centers differ in their action if the results are inconclusive | Hospitals differed on histological confirmation of all potential metastatic disease: some always used histological confirmation, and others used it depending on whether it was important for the decision and according to the reliability of the radiological characteristics |
• • Fitness test versus medical history and clinical examination | The patient’s physical functioning was assessed differently. Some hospitals conducted fitness tests | ||
• • Standard • No restaging • High-risk patients for interval metastasis | Half of the hospitals performed restaging by PET-CT or CT after neoadjuvant therapy, leading to avoidance of unnecessary surgery in patients diagnosed with interval metastasis | ||
| Clinical examination of the patient’s physical and cognitive functioning | • • Standard arrangements versus based on clinical assessment | Some hospitals consulted non-upper-GI specialists, such as anesthesiologists, prior to TDM. A geriatric assessment was standard in some hospitals in patients above a certain age, to determine mental fitness and frailty, while others only consulted a geriatrician if deemed necessary | |
• • Boosting of physical functioning versus less invasive treatment choice • Active Pre-habilitation programs versus advice/referral | Some hospitals offered a formal pre-habilitation program, including physical therapy and the consultation of a dietician, to improve physical fitness, whereas others only advised patients to improve their physical fitness |
Categories in bold are discussed in the result section of this article, TDM Treatment decision-making, MDTM multidisciplinary team meeting
Fig. 1Parts of an integrated clinical pathway according to the hospital of diagnosis on regional, local and patient level. Based on the observations all hospitals are displayed in this figure. Each included hospital is represented by the form of a circle including a hospital number. In addition the probability groups are represented by different shades of gray. The referring hospital is not represented in this figure